Provided by Tiger Trade Technology Pte. Ltd.

Novo Nordisk A/S B Shares ADRhedged

25.35
+0.11030.44%
Post-market: 25.350.00000.00%16:15 EDT
Volume:499
Turnover:12.63K
Market Cap:4.06M
PE:- -
High:25.35
Open:25.33
Low:25.33
Close:25.24
52wk High:34.36
52wk Low:19.00
Shares:160.00K
Float Shares:160.00K
Volume Ratio:0.57
T/O Rate:0.31%
Dividend:1.70
Dividend Rate:6.69%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Exchange Traded Funds Top 10 Percentage Losers

Dow Jones
·
Aug 01

Nasdaq Composite Index Rises 1% as Amazon Surges 15% After Results; Apple and Micron Fall as Memory Stocks Retreat

TradingKey
·
Aug 01

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

TIPRANKS
·
Aug 01

European Stocks Wipe Out Monthly Gains as Novo Nordisk and Universal Music Plunge

Deep News
·
Aug 01

Canada Net Change Percentage Gainers & Losers

Dow Jones
·
Aug 01

Novo Nordisk A/S Stock (NVO) Moved Down by 8.75% on Jul 31: Key Drivers Unveiled

TradingKey
·
Aug 01

European Equities Mixed in Friday Trading; Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Trial

MT Newswires Live
·
Aug 01

Novo Nordisk A/S Series B Stock Falls Friday, Underperforms Market

Dow Jones
·
Aug 01

Novo Nordisk Falls Over 10% in Largest Single-Day Drop in Nearly Five Months After Announcing Heart Drug Trial Failure

TradingKey
·
Jul 31

Novo Nordisk's Stock Slumps After Failed Trial - Adding to the Company's Woes

Dow Jones
·
Jul 31

Novo Nordisk Heart Drug Trial Failure Triggers Pre-Market Plunge, Deepening Concerns Over Weight Loss Drug Reliance

Stock News
·
Jul 31

Sector Update: Healthcare

MT Newswires Live
·
Jul 31

Novo Nordisk Share Fall Seems Justified by Loss of Big Sales Opportunity

Dow Jones
·
Jul 31

Cardiac Drug Trial Failure Sinks Novo-Nordisk Stock Over 9%

Deep News
·
Jul 31

Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Phase 3 Trial; Shares Fall Pre-Bell

MT Newswires Live
·
Jul 31

Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events Risk in Phase 3 Trial

MT Newswires Live
·
Jul 31

Here Comes the Next Wave of GLP-1s. They'll Treat a Lot More than Obesity.

Dow Jones
·
Jul 31

Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Jul 30

Novo Nordisk Faces Shareholder Lawsuit Over New Generation Weight Loss Drug - Full Timeline

Deep News
·
Jul 29

Wall Street Analysts Are Neutral on Top Healthcare Picks

TIPRANKS
·
Jul 28